In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin

[1]  H. Hansen,et al.  Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance. , 1993, Biochemical pharmacology.

[2]  K. Kohn,et al.  Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. , 1993, Blood.

[3]  J. Alsner,et al.  Mode of action of topoisomerase II-targeting agents at a specific DNA sequence. Uncoupling the DNA binding, cleavage and religation events. , 1992, Journal of molecular biology.

[4]  C. Potten.  The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice , 1992, Cancer and Metastasis Reviews.

[5]  J. Wang,et al.  Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. , 1992, Cancer research.

[6]  C. Sarraf,et al.  The nature of cytotoxic drug-induced cell death in murine intestinal crypts. , 1992, British Journal of Cancer.

[7]  Z. Darżynkiewicz,et al.  Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells. , 1992, Cancer research.

[8]  H. Hansen,et al.  Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II. , 1991, Cancer research.

[9]  P. Walker,et al.  Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. , 1991, Cancer research.

[10]  E. Alnemri,et al.  Activation of internucleosomal DNA cleavage in human CEM lymphocytes by glucocorticoid and novobiocin. Evidence for a non-Ca2(+)-requiring mechanism(s). , 1990, The Journal of biological chemistry.

[11]  H. Hansen,et al.  Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. , 1990, Cancer research.

[12]  H. Hansen,et al.  In vitro evaluation of the potential of aclarubicin in the treatment of small cell carcinoma of the lung (SCCL). , 1989, British Journal of Cancer.

[13]  J. Bennett,et al.  Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia. , 1988, Blood.

[14]  E. Thiel,et al.  Aclarubicin (aclacinomycin A) in the treatment of relapsing acute leukaemias. , 1985, European journal of cancer & clinical oncology.

[15]  L. Liu,et al.  Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. , 1984, Science.

[16]  N. Nissen,et al.  Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunorubicin and cytarabine: a phase II trial , 1984, Cancer treatment reports.

[17]  R. Warrell,et al.  Phase I--II evaluation of a new anthracycline antibiotic, aclacinomycin A, in adults with refractory leukemia. , 1982, Cancer treatment reports.

[18]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[19]  K. Danø.  Development of resistance to daunomycin (NSC-82151) in Ehrlich ascites tumor. , 1971, Cancer chemotherapy reports.

[20]  C. Keele,et al.  The Principles of Chemotherapy , 1952, Postgraduate medical journal.

[21]  Shinobu Nakamura,et al.  Salvage chemotherapy of refractory non-Hodgkin's lymphoma with aclacinomycin, behenoyl ara-C, etoposide, and prednisolone , 2004, Cancer Chemotherapy and Pharmacology.

[22]  亀崎 佐織.  bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair , 1996 .

[23]  P. Borst.  Genetic mechanisms of drug resistance. A review. , 1991, Acta oncologica.

[24]  P. Workman,et al.  9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. , 1990, European journal of cancer.

[25]  L. Liu,et al.  DNA topoisomerase poisons as antitumor drugs. , 1989, Annual review of biochemistry.

[26]  J H Goldie,et al.  Rationale for the use of alternating non-cross-resistant chemotherapy. , 1982, Cancer treatment reports.

[27]  A. Wyllie,et al.  Cell death: the significance of apoptosis. , 1980, International review of cytology.